The Biggest Eli Lilly GLP-1 Stories of 2026 So Far

Coming into 2026, Eli Lilly had the best-selling medicine in the world, a trillion-dollar valuation and an obesity pill waiting on the FDA. Nine months later it has four approved tirzepatide uses, a pill that launched into a market its rival got to first, and the largest weight-loss numbers ever reported for a drug still sitting in trials.

Here is the year through September 14, 2026, with sources. This is a news recap, not medical guidance. Nothing here is a recommendation about any treatment.

What happened with Lilly’s obesity pill?

Everything, and in a strange order.

Lilly spent the first quarter preparing. By February its pre-launch stockpile of orforglipron had reached about $1.5 billion, roughly triple the level a year earlier, an unusual bet meant to avoid repeating the tirzepatide shortages [1]. On February 26, the head-to-head ACHIEVE-3 trial published in The Lancet, showing the pill beating Novo’s oral semaglutide on blood sugar and weight in type 2 diabetes, and also producing more gastrointestinal side effects and more discontinuations [2].

On April 1, 2026, the FDA approved it as Foundayo, described as the only GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions [3]. The label the agency posted the same day sets out the dosing schedule and warnings [4]. It reached US pharmacies on April 9 through LillyDirect, telehealth partners and retail chains, at a self-pay price of $149 a month for the lowest dose [5], and Amazon said it would stock it at pharmacy kiosks with same-day delivery [6].

Then the safety conditions attached to that approval became a story of their own. The FDA’s approval letter, posted on April 14, required Lilly to run studies of cardiovascular events, drug-induced liver injury and delayed gastric emptying, and to submit pediatric data [7]. Postmarketing requirements like these are a standard condition of a new drug approval rather than a special intervention, but they drew attention because they followed reporting in December 2025 that FDA leaders had pushed staff to compress the review. Lilly published data from ACHIEVE-4, its longest phase 3 study, two days later, reporting that the cardiovascular and overall safety profile held up [8].

Commercially, the launch has been slower than the science. Foundayo passed roughly 1,000 prescriptions in its first days, about 7,000 a week by early May [9], and Lilly said in its second-quarter results that the pill had disappointed while injectables kept booming [10]. Prescription tracking in September showed both obesity pills still climbing, with Novo’s Wegovy pill holding the lead it built with a three-month head start [11].

Did Zepbound get its insurance coverage back?

Yes, with a date.

On May 28, 2026, CVS Caremark announced it would restore Zepbound to its commercial formularies as a preferred option from October 1, and lift the standard new-to-market block on Foundayo from June 1 [12]. That reversed the May 2025 exclusion that had moved hundreds of thousands of patients onto Wegovy, and it put Lilly and Novo Nordisk back on equal footing on the largest commercial template in the country.

The reversal followed a year of patient complaints, a class action filed in September 2025 and Lilly pulling its own employees’ drug benefit away from CVS.

Why did Novo Nordisk sue Eli Lilly?

Over advertising.

On July 21, 2026, Novo Nordisk sued Lilly, alleging its comparative GLP-1 advertising was false and misleading and ignored the science [13]. Three days later Novo moved for a preliminary injunction to stop the ads outright [14]. Lilly has said its claims rest on published randomized trials, chiefly SURMOUNT-5.

The suit is the sharpest expression of a fight that has been building since 2024. Both companies are among the largest consumer advertisers in the United States, and in May 2026 the French medicines regulator fined both of them over obesity drug promotion.

What did Mounjaro get approved for in 2026?

Heart protection.

On August 27, 2026, the FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes, and Lilly announced it the next day [15]. The approval rests on SURPASS-CVOT, the head-to-head trial against Trulicity reported in July 2025.

This matters commercially more than it might sound. Until then, one of Novo Nordisk’s strongest arguments was that only semaglutide had a proven cardiovascular indication. A survey of prescribers in September found the new label was likely to shift prescribing in type 2 diabetes.

Earlier in the year, on February 23, the FDA also cleared the multi-dose Zepbound KwikPen, which packs a month of weekly doses into a single device [16]. On the same day, Novo’s next-generation CagriSema failed even to match Zepbound in the head-to-head REDEFINE 4 trial, missing its non-inferiority endpoint with 23% average weight loss against 25.5% on tirzepatide at 84 weeks. Novo’s Copenhagen shares closed down 16.5% [17].

How big are retatrutide’s numbers?

Bigger than anything else, and complicated.

Lilly’s triple agonist hits GIP, GLP-1 and glucagon receptors. In March it cleared its first phase 3 diabetes trial with 16.8% weight loss alongside large A1C reductions. On May 21 the TRIUMPH-1 topline reported an average of 28.3%, or 70.3 lbs, at 80 weeks on the 12 mg dose, with 45.3% of that group losing 30% or more of their body weight — what reporters described as bariatric-surgery territory. The same topline reported up to 30.3%, or 85.0 lbs, at 104 weeks in a prespecified extension restricted to participants who began with a BMI of 35 or higher [18]. At the American Diabetes Association meeting in June, Lilly presented the full package, showing gains in weight, blood sugar, knee osteoarthritis pain and obstructive sleep apnea [19]. In July, two more trials completed the phase 3 program and Lilly set a first-quarter 2027 filing.

The complications are three. Discontinuation rates in the trials have been high enough that analysts keep flagging them. Lilly and the FDA have been working through whether retatrutide is legally a biologic, which determines its exclusivity and how any copy would be approved. And an unapproved drug has acquired a consumer market.

That last one became a real story in 2026. In June, CBS News documented clinicians promoting and selling retatrutide sourced from research-chemical suppliers. STAT reported that Lilly had granted compassionate-use access to a single 79-year-old patient, and Democratic lawmakers asked the White House who that was [20]. Lilly opened a broader expanded-access application process in August, then sued six companies over alleged illegal sales and publicly asked online platforms and payment processors to cut sellers off [21].

Is the compounded tirzepatide market finally over?

Close to it, and for a reason that has nothing to do with enforcement.

Prices came down. Doctors told Reuters in May that the combination of cheap branded pills and discounted Zepbound vials was finally pulling patients out of the compounded market, five years after it started.

Enforcement helped. On March 12, Lilly published an open letter saying testing of tirzepatide compounded with vitamin B12 had found high levels of an impurity, and urged prescribers and patients to avoid those products [22]. On April 30, the FDA proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulk substances list, finding no clinical need for outsourcing facilities to compound them from bulk [27]. That would close the largest-scale compounding route, though it does not by itself govern smaller 503A pharmacies, and it is still only a proposal: the comment period ran to July 30, 2026 and the agency had not issued a final determination as of September 14, 2026. In August a court dismissed an antitrust suit brought by a compounder alleging Lilly and Novo Nordisk had conspired to shut competitors out.

What is Lilly doing with all the money?

Buying things and building things.

The acquisitions in 2026 alone include Ventyx Biosciences for $1.2 billion in January [23], a narcolepsy drugmaker for up to $7.8 billion in March, Merida Biosciences for up to $2.88 billion in August, and the completion of the AtaiBeckley deal in September. It also signed a $1.3 billion oral obesity research deal with Nimbus in January [24] and opened a joint AI lab with NVIDIA.

The factories kept coming too: a $3.5 billion Pennsylvania plant in January designated for retatrutide, a $3 billion China expansion in March, and a $750 million device and fill-finish partnership in July.

Financially it has worked. Fourth-quarter 2025 results in February showed Mounjaro and Zepbound at $11.7 billion for the quarter [25]. First-quarter 2026 revenue rose 56% and the stock jumped 10% [26]. Second-quarter revenue rose 48%. Not every analyst is convinced: HSBC issued a rare downgrade in March, questioning whether the market was valuing the pill story and Zepbound’s growing cash-pay mix too generously.

What should you watch for the rest of the year?

Four things, all dated.

CVS Caremark’s restored Zepbound coverage takes effect October 1. Foundayo’s prescription trajectory will show by the fourth quarter whether the slow start was a launch problem or a product problem. The retatrutide classification question with the FDA needs resolving before the first-quarter 2027 filing. And the federal litigation over gastrointestinal injuries, which names Lilly’s Mounjaro and Trulicity alongside Novo Nordisk’s semaglutide products, reached its Rule 702 hearing on general causation before Judge Karen S. Marston in the Eastern District of Pennsylvania, running September 14 to 18, 2026 [28]. That ruling decides whether the plaintiffs’ causation experts can testify, and no bellwether trial has been scheduled.

As always, none of this is advice about your own treatment. If you are taking or considering any of these medicines, that conversation belongs with a healthcare provider.

Sources

1. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision — Reuters, February 13, 2026
2. Lilly’s oral GLP-1 orforglipron delivered superior blood sugar control and weight loss compared to oral semaglutide — PR Newswire / Eli Lilly, February 26, 2026
3. FDA approves Lilly’s Foundayo (orforglipron) — PR Newswire / Eli Lilly, April 1, 2026
4. FOUNDAYO (orforglipron) tablets — original FDA label — FDA, April 1, 2026
5. Foundayo, Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. — PR Newswire / Eli Lilly, April 9, 2026
6. Amazon to stock Lilly’s new weight-loss pill at U.S. kiosks, offer same-day delivery — CNBC, April 9, 2026
7. FDA seeks added safety data from Lilly on newly approved weight-loss pill — CNBC, April 14, 2026
8. ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo to date, reaffirmed its cardiovascular and overall safety profile — PR Newswire / Eli Lilly, April 16, 2026
9. Lilly’s obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake — Reuters, May 8, 2026
10. While sales of Lilly’s obesity pill disappointed in Q2, injectables continue to boom — Fierce Pharma, August 5, 2026
11. The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb — Fierce Pharma, September 11, 2026
12. CVS to restore coverage of Zepbound, add Eli Lilly’s obesity pill to drug plans — CNBC, May 28, 2026
13. Novo sues Lilly, claiming misleading ads in weight-loss drug battle — Reuters, July 21, 2026
14. Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads — Reuters, July 24, 2026
15. FDA approves Lilly’s Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes — Eli Lilly, August 28, 2026
16. Zepbound now available in multi-dose KwikPen — PR Newswire / Eli Lilly, February 23, 2026
17. Novo Nordisk’s CagriSema trial deals blow in obesity drug battle with Eli Lilly — Reuters, February 23, 2026
18. Lilly’s triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial — Eli Lilly, May 21, 2026
19. Lilly’s triple agonist retatrutide drove substantial improvements in weight, A1C, knee osteoarthritis pain and obstructive sleep apnea — PR Newswire / Eli Lilly, June 6, 2026
20. Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient — STAT, June 23, 2026
21. Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide — Reuters, August 12, 2026
22. An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 — Eli Lilly, March 12, 2026
23. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal — Reuters, January 7, 2026
24. Nimbus, Lilly sign deal to develop new oral obesity drug — Reuters, January 6, 2026
25. Lilly takes another victory lap as Zepbound, Mounjaro sales hit $11.7B in Q4 — FirstWord Pharma, February 4, 2026
26. Lilly reports first-quarter 2026 financial results, raises full-year guidance — PR Newswire / Eli Lilly, April 30, 2026
27. FDA proposes to exclude semaglutide, tirzepatide and liraglutide on the 503B bulks list — FDA, April 30, 2026
28. MDL 3094, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation — court notices — US District Court, Eastern District of Pennsylvania, accessed September 14, 2026